AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05380466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantum Touch
Description: Quantum-Touch is one of the therapeutic touch techniques, a biofield therapy that uses life force energy to facilitate healing
Study NCT04733768 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007
Description: 18f-PSMA-1007 PET/CT scan
Study NCT06356337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light goggles
Description: Blue light goggles designed to promote circadian entrainment will be worn for 1 hour each morning for two weeks.
Study NCT06356337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orange glasses
Description: Orange glasses that do not provide entrainment will be worn for 1 hour each morning to block morning light for two weeks.
Study NCT06239272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Low, Intermediate and High-risk Surgery to remove tumor (standard of care)
Study NCT06239272 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam radiation therapy
Description: Low, Intermediate and High-risk Radiation therapy is considered standard of care for patients with NRSTS who have positive tumor margins. However, the dose that will be given in this study is higher than what is usually given, therefore, the dose of radiation in this study is research. Radiation will start about 3 to 6 weeks after your surgery, depending on how quickly you recover from surgery. Radiation will be given daily (Monday through Friday) for about 5 to 6 weeks.
Study NCT06239272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Intermediate and High-risk By mouth, either by tablet or a liquid suspension, 7 doses, days 1 to 7
Study NCT06239272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Intermediate and High-risk Ifosfamide is a structural analogue of cyclophosphamide. Into the vein (IV) over about 3 hours, 3 doses, days 1, 2, and 3
Study NCT06239272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Intermediate and High-risk An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Intermediate, High-risk Into the vein (IV) over about 1 hour, 2 doses, days 1 and 2
Study NCT06239272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: High-risk Dosage and route of administration: Selinexor tablets for oral administration should be taken at approximately the same time each day without regards to meals.~Selinexor is a selective inhibitor of nuclear export (SINE). Selinexor specifically blocks XPO1-mediated nuclear export by forming a slowly reversible covalent bond with the nuclear export protein XPO1 By mouth, either by tablet or a liquid suspension, 1 dose and day 3
Study NCT06582225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered exposure and response prevention (I-ERP)
Description: The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, emotions, healthy habits, the difference between repetitive behaviours in autism and OCD, how compulsions maintain the obsessions, and the rationale for ERP. The main focus of the treatment is ERP tasks based on the young person's individual goals. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of ERP. The final module includes a summary of the treatment and a relapse prevention plan.~The version for parents consists of the same content as the child treatment, but with elaborated psychoeducation, and additional focus on strategies on how to assist their child in the different exposure tasks.
Study NCT06582225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered stress management (I-SM)
Description: The intervention is internet-delivered and therapist-guided, involving the child and at least one caregiver. It consists of two separate sets of modules, one for the child and one for the caregiver. The intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The treatment includes psychoeducation about ASD, OCD, healthy habits, and how stress is a contributor to OCD symptoms. The rationale is that targeting and reducing stress will have a beneficial impact on anxiety, obsessions, and compulsions. The main goal of the treatment is to learn how to reduce stress, mainly by using relaxation techniques such as deep breathing, progressive muscle relaxation, and imagery (cognitive) relaxation. The modules also contain homework tasks that are meant to be completed between modules, mainly consisting of relaxation tasks.~The version for parents contains psychoeducation, as well as strategies on how to assist their child in the different relaxation tasks.
Study NCT06527066 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Geranium (Pelargonium graveolens) essential oil (EO) diluted to 1% in All.me Beauty® Gel Sérum Biocompatível
Description: Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, in relation to the item Instrumental Facial Assessment, before treatment and after four, eight and 12 weeks.
Study NCT06527066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gel Sérum Biocompatível All.me Beauty®
Description: Volunteers must use a total of one gram of the formulation on their face, twice a day, in the morning and at night. The total duration of the protocol will be 12 weeks, with assessment of the participants' skin conditions, in relation to the item Instrumental Facial Assessment, before treatment and after four, eight and 12 weeks.
Study NCT04850105 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Data on each patient will be collected at study enrollment and at each follow-up visit.~No mandatory visits, tests, or assessments are required for this study. All visits will be scheduled and conducted according to the clinical site's normal clinical practice.
Study NCT05355701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07799933
Description: Tablet
Study NCT05355701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Tablet
Study NCT05355701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Injection for intravenous use
Study NCT04993885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: The subjects will receive avatrombopag treatment with an initial dose of 40mg once a day. Platelet counts will be obtained weekly during the first 4 weeks and then every 2 weeks until week 12 after treatment. The dose adjustment range is 20 mg per week to 40 mg per day to maintain the platelet level between 30×10\^9/L and 200×10\^9/L. If the platelet count does not reach to 30×10\^9/L after taking avatrombopag 40mg once a day for 4 consecutive weeks, the treatment will be stopped.
Study NCT06474286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride 1 MG
Description: The study drug Tab. Prucalopride 1 mg (30 tablets) will be dispensed to the participant. The drug will be procured at the local site manufactured in India only.They will be explained to take one tablet of 1 mg Prucalopride per oral in the morning. The participants will continue their antipsychotic regimen as per orders of their consultant and will continue to purchase their psychiatric medications as earlier. At the end of week 1, participants will be assessed for side effects via telephonic conversation.
Study NCT05139992 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Vaccination against SARS-CoV-2
Study NCT05017363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENGAGE
Description: Goal-setting approach and strategies including the Perceived Efficacy and Goal Setting Tool (PEGS), which is established goal setting tools for children aged 5-9. Administration of the Canadian Occupational Performance Measure (COPM), the most widely used goal-setting tool in paediatric rehabilitation that has been used with children as young as seven years. Introducing simple strategies to assist children in identifying goals and to ensure ongoing focus on goals using principles of motivational interviewing, strategies to assess and nurture perceived competence (self-efficacy), and child-friendly feedback strategies on goal-related performance.
Study NCT05287113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab 500mg will be administered intravenously every 4 weeks.
Study NCT05287113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02385
Description: INCAGN02385 350mg will be administered intravenously every 2 weeks.
Study NCT05287113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: INCAGN02390 400 mg will be administered intravenously every 2 weeks.
Study NCT05287113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered intravenously.
Study NCT03732417 — intervention group
Intervention type: OTHER
Intervention: Secondary prevention of cardiovascular risk factors
Description: Intervention group (n=35) Control group (n=35)
Study NCT06610136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine plus Resistance training
Description: Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
Study NCT06610136 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Resistance training
Description: Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
Study NCT06368050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: practice structure intervention
Description: practice structure intervention
Study NCT05173194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Eight-week program of a remotely supervised resistance exercise. Frequency: three times per week. Duration: 60 minutes per session. Training program: warm-up and joint mobility; strength exercises for different muscle groups; and cool down (stretching and breathing exercises).
Study NCT05586581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SV2A PET
Description: SV2A PET scan with radiotracer \[11C\]UCB-J for imaging synaptic density in the brain
Study NCT05586581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSPO PET
Description: TSPO PET scan with radiotracer \[11C\]PBR28 for imaging of neuroimmune status
Study NCT05741424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Innovative diagnostic technologies
Description: Samples from patients positive for Gram-negative bacteremia will be analyzed using the new BacT/Alert® VIRTUO®, BioFire® BCID2 and REVEAL® diagnostic solutions
Study NCT05741424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reference diagnostic technique
Description: Analysis of samples using diffusion on Mueller Hinton (MH) agar medium according to EUCAST.
Study NCT05294588 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cefixime
Description: Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
Study NCT05294588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
Study NCT05294588 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ceftriaxone
Description: Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
Study NCT05294588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of clinically apparent urethritis or on the 10th study day after inoculation.
Study NCT05294588 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin
Description: Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positive N. gonorrhoeae test within 1 week post initial antibiotic treatment
Study NCT05294588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positive N. gonorrhoeae test within 1 week post initial antibiotic treatment
Study NCT05294588 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Neisseria gonorrhoeae strain FA1090
Description: 0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
Study NCT05294588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neisseria gonorrhoeae strain FA1090
Description: 0.4 mL of a suspension containing 10\^5 - 10\^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
Study NCT05294588 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal Group B Vaccine
Description: All participants will receive 2 doses of the 4CMenB vaccine, 0.5 mL intramuscularly
Study NCT05294588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Group B Vaccine
Description: All participants will receive 2 doses of the 4CMenB vaccine, 0.5 mL intramuscularly
Study NCT05294588 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza Vaccine
Description: All participants will receive the quadrivalent influenza vaccine, 0.5 mL intramuscularly.
Study NCT05294588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: All participants will receive the quadrivalent influenza vaccine, 0.5 mL intramuscularly.
Study NCT05294588 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Tetanus-diptheria Vaccine
Description: All participants will receive the Td vaccine, 0.5 mL intramuscularly.
Study NCT05294588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus-diptheria Vaccine
Description: All participants will receive the Td vaccine, 0.5 mL intramuscularly.
Study NCT06184529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The virtual reality simulation includes a one time viewing of a brief video tutorial and then trying out a one time virtual reality simulation with a child avatar that takes 10-20 minutes to complete in-person.
Study NCT05018000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial navigation
Description: The CAFÉ intervention is a financial navigation intervention. During the Intervention, a CAFÉ financial navigator will provide information support and resources to people with cancer after diagnosis. CAFÉ intervention components include: (1) proactive assessment of patient financial questions and concerns (e.g., acute financial need or inability to pay for household expenses; deciding between care options depending on cost; uncertainty around planning for out of pocket costs and/or when patients will need to pay), (2) proactive, personalized support and referrals.
Study NCT05018000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: The financial resource sheet lists and describes existing internal and community resources available to KP members
Study NCT05062174 — intervention group
Intervention type: DRUG
Intervention: Mifepristone 200 MG
Description: Orally, one time dosage of 200 mg
Study NCT05062174 — intervention group
Intervention type: PROCEDURE
Intervention: Prophylactic mastectomy
Description: Planned prophylactic mastectomy (having one or both breasts removed).
Study NCT06022861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01015
Description: Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, thereafter, 480mg every 4 weeks(Q4W) during the maintenance treatment period
Study NCT06022861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Intravenouslly (IV) l 800mg/m2 every 4 weeks (（on Day 1 through Day 5)during the combined chemotherapy period
Study NCT06022861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Intravenouslly (IV) l 800mg/m2 every 4 weeks (（on Day 1 through Day 5)during the combined chemotherapy period
Study NCT06022861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenouslly (IV) 80mg/m2 every 4 weeks (Q4W) during the combined chemotherapy period
Study NCT06022861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Intravenouslly (IV) 80mg/m2 every 4 weeks (Q4W) during the combined chemotherapy period
Study NCT06022861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opdivo®
Description: Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, 480mg every 4 weeks(Q4W) during the maintenance treatment period within 24 weeks, thereafter converted to LY01015 480mg every 4 weeks(Q4W).
Study NCT06204965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Time-restricted eating (TRE) is a dietary pattern where food intake is restricted to 8 hours of the day with no limitation on nutrient quality or quantity. Participants assigned to the intervention group will eat their usual diet from 9:00 a.m. to 5:00 p.m., and then fast until the next day (protocol 8/16). During the 16-hour fast, only hot and cold drinks will be allowed, i.e. coffee, tea or tea and water, but all products and dishes with energy value (including coffee cream, sweet teas, alcohol, snacks, etc.) will be prohibited. The TRE protocol will be implemented 7 days a week for a period of 3 months (12 weeks).
Study NCT04942574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Description: Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of total sleep deprivation.
Study NCT04942574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal sleep
Description: Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of normal sleep.
Study NCT06562205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP System A (with Amalfi) then PAP System B (with CLA11)
Description: PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
Study NCT06562205 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP System A (with Amalfi) then PAP System B (with CLA11)
Description: PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days
Study NCT06562205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP System B (with CLA11) then PAP System A (with Amalfi)
Description: PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
Study NCT06562205 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP System B (with CLA11) then PAP System A (with Amalfi)
Description: PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
Study NCT04742491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Arm Truvada in the US
Description: Truvada in the United States
Study NCT04742491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferred Intervention Arm Truvada in the US
Description: Truvada in the United States
Study NCT04742491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Arm Truvada in Brazil
Description: Truvada in Brazil
Study NCT04742491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferred Intervention Arm Truvada in Brazil
Description: Truvada in Brazil
Study NCT04742491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Arm Descovy in the US
Description: Descovy in the United States
Study NCT04742491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferred Intervention Arm Descovy in the US
Description: Descovy in the United States
Study NCT05872737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB)
Description: The Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB) is a 12-week self-help parenting program that integrates Acceptance and Commitment Therapy (ACT) principles with web-based modules and group-based sessions. The program includes a self-help workbook/manual and ACT protocols that cover various self-help exercises such as guided imagery, grounding, mindfulness, and values clarifications. To make the programme more relatable to Hong Kong parents caring for children with NDD, storytelling vignettes and therapeutic narratives will be included. Parents will work on each module at their own pace within 2-3 weeks and meet with trained facilitators in a video-conferencing format after completing each module to review their progress and learn positive parenting techniques.